RNAZHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 12 Sept 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores TransCode Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (86): Smaller than most of the companies we track.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RNAZ, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | $20 → $10 |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2023 | HC Wainwright & Co. | Reiterates | Buy | $3.00 |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 15 Nov 2022 | HC Wainwright & Co. | Maintains | Buy | $10 → $6.00 |
| 7 June 2022 | HC Wainwright & Co. | Initiates | Buy | $10 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNAZ appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 75% of US stocks
Cheaper than 92% of US stocks
Cheaper than 82% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 19% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
TransCode Therapeutics, Inc. has a market value of $1.8M and an enterprise value of $186.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$42.8M.
Free cash flow in the twelve months to 30 June 2026: −$22.6M.
Trailing P/E: 0.0×; forward P/E: −2.8× — the forward figure prices analyst consensus estimates, not reported earnings.
TransCode Therapeutics, Inc. employs 12 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own TransCode Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
TransCode Therapeutics announced that Chief Financial Officer Tom Fitzgerald is retiring. John Tattory will assume the role of Interim Chief Financial Officer as the company manages this leadership transition.
Why it matters — A change in the CFO role is a significant leadership transition for the clinical-stage company that RNAZ watchers may want to monitor.
TransCode Therapeutics announced the publication of a peer-reviewed article in Cancers reporting that its lead candidate, TTX-MC138, showed significant survival benefits in a preclinical model of breast cancer bone metastasis, with favorable tolerability and no observed systemic toxicity.
Why it matters — This publication provides preclinical evidence supporting the therapeutic potential of TransCode's lead candidate in a hard-to-treat metastatic setting, which is relevant to the company's pipeline progress.
Of the 1 analysts covering TransCode Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TransCode Therapeutics, Inc. 22 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, TransCode Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).
No analyst covering TransCode Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNAZ are extrapolating price history, which says nothing about the business.
TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies and immuno-oncology programs for high-risk and advanced cancers.
The most recent item we track (PRNewsWire, 10 Sept 2026): "TransCode Therapeutics Announces Leadership Transition". TransCode Therapeutics announced that Chief Financial Officer Tom Fitzgerald is retiring. John Tattory will assume the role of Interim Chief Financial Officer as the company manages this leadership transition.
TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies and immuno-oncology programs for high-risk and advanced cancers. The company’s current work centers on targeted cancer therapeutics designed to address metastatic disease, including candidates that modulate microRNA pathways and other genetic mechanisms linked to tumor growth and spread. Its pipeline also includes programs exploring RNA delivery platforms and combination approaches aimed at improving how nucleic-acid medicines reach cancer cells. TransCode Therapeutics operates within the oncology and RNA therapeutics segments of the life sciences market, where it contributes to the development of precision treatments for difficult-to-treat malignancies. Headquartered in Boston, Massachusetts, the company concentrates on advancing experimental cancer therapies through clinical and preclinical development.
CEO Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. · 12 employees · United States · https://www.transcodetherapeutics.com